

BAB V

PENUTUP

5.1 Kesimpulan

Dari uraian pembahasan diatas dapat kita simpulkan bahwa berdasarkan hasil studi literatur yang sudah dilakukan, efek samping NSAID yang sering terjadi adalah gangguan saluran cerna (iritasi lambung, mual dan muntah).

5.2 Saran

Adapun saran yang dapat disampaikan yaitu :

1. Perlu adanya komunikasi antara farmasis dengan dokter mengenai peresepan dosis dan obat NSAID demi tercapainya terapi yang baik dan meminimalisir efek samping.
2. Adanya masalah terkait dengan penggunaan terapi OA, khususnya obat golongan NSAID terutama pada pasien usia lanjut menuntut Farmasi untuk lebih berperan aktif dalam memberikan *Pharmaceutical Care*, seperti pemberian konseling sehingga dapat mencegah terjadinya efek samping potensial dan aktual serta adanya interaksi potensi guna meningkatkan kualitas hidup pasien.

5.3 Keterbatasan Penelitian

Adapun keterbatasan dalam penelitian ini adalah:

1. Keterbatasan ruang dan waktu penelitian sehingga menyebabkan peneliti kurang maksimal dalam melaksanakan penilitan.

2. Kesulitan yang dihadapi peneliti dalam menemukan atau mencari jurnal yang sesuai dengan judul penelitian.
3. Studi Literatur tergolong penelitian baru, jadi peneliti mengalami sedikit kesulitan dalam pembahasan.



DAFTAR PUSTAKA

- Allredge BK, Affairs A, Francisco S, Corelli RL, Ernst ME, City I, et al. *Koda-Kimble and Young's Applied Therapeutic: The Clinical Use of Drug*. 10th ed. Philadelphia: Lippincot Williams and Wilkins; 2013.
- Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). *Saudi Pharm J*. King Saud University; 2014 Apr;22(2):83–94.
- America Medical. 2011. *American Medical Association family medical guide*. Wiley. United State of America
- Amrulloh FM. 2016. *Hubungan Konsumsi OAINS terhadap Gastritis*. Lampung: Universitas Lampung.
- Arthritis Foundation. 2017. What is Osteoarthritis. <http://www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php> di akses pada Selasa 23 Mei 2017
- Barus J. (2015). *Continuing Medical Education Penatalaksanaan Farmakologis Nyeri Pada Lanjut Usia*. Jakarta: Departemen Neurologi Fakultas Kedokteran Universitas Atma Jaya.
- Bensen MD. et al. 1999. Treatment of Osteoarthritis With Celecoxib, a Cyclooxygenase-2 Inhibitor: A Randomized Controlled Trial. *Mayo Clinic Proceedings* Volume 74, Issue 11
- Buys, Lucinda M., Elliott, Marry E., Osteoarthritis in: DiPiro, Joseph T., Buys, Lucinda M., Elliott, Mary E., Talbert, RL., Yee, GC., Matzke, GR., Wells, BG., Posey, LM., 2014. *Pharmacoterapy a Pathophysiologic Approach* 9th Ed. USA: McGraw-Hill education, p. 9–15.
- Center of Disease. 2017. Osteoarthritis. <https://www.cdc.gov/arthritis/basics/> Di akses pada Senin 29 mei 2017
- Cimolai, N., 2013. The potential and promise of mefenamic acid. *Expert Reviews Clinical Pharmacology*. Vol. 6, No. 3, p. 289–305
- Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. 2014 - cross et al - The global burden of hip and knee osteoarthritis estimates from the global burden of disease 2010 study. *Ann Rheum Dis*. 2014;73(7):1323–30.
- Departemen Kesehatan RI. 2006. *Pharmaceutical Care Untuk Pasien Penyakit Artritis Rematik*. Jakarta
- De Lange-Brokaar BJE, Ioan-Facsinay A, van Osch GJVM, Zuurmond A-M, Schoones J, Toes REM, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. *Osteoarthritis Cartilage*. Elsevier Ltd; 2012 Dec;20(12):1484–99.

- Dieppe PA. 1995. *Osteoarthritis In : Kippel JH, Dieppe PA. Practical Rheumatology*. London : Mosby
- Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L. *Pharmacotherapy: Pathophysiologic Approach*. 7 Ed. USA: The McGraw-Hill Companies, Inc; 2008.
- Dipiro., et al. 2009. *Pharmacotherapy Handbook 7th Edition*. The McGraw-hill. United State of America
- Doherty, M.J. 2009. Algorithms for assessing the probability of an Adverse Drug Reaction. *Respiratory Medicine CME*, 2(2):63-67
- Embun, B. (2012, April 17). *Banjir Embun*. Retrieved from Penelitian Kepustakaan: <http://banjirembun.blogspot.co.id/2012/04/penelitian-kepustakaan.html>
- Epstein, BJ., *Osteoarthritis in: Dipiro, JT., Gums, GJ., Hall, Karen., Burns, Marie A., Wells, Barbara G., Schwinghammer, Terry L., Malone, Patrick M., Kolesar, Jill M., Rotschafer, J.*, 2008. ***Pharmacoterapy Pinciples and Practice***. 8th Ed. New York: The McGraw-Hill Companies Inc, p. 879 – 890
- Felson, David.T; Yuqing Zhang. 1998. *An Update on the Epidemiology of Knee and Hip Osteoarthritis with a View to Prevention*. Journal of American College of Rheumatology Val. 41, No. 8
- Finkel, Richard; Clark, Michelle A; Cubeddu, Luigi X. 2009. *Farmakologi Ulasan Bergambar Edisi 4*. EGC. Jakarta
- Finkel, Richard; Clark, Michelle A; Jose, A Rey; Karen, Whalen. 2012. *Pharmacology 5th Edition*. Lippincott Williams & Wilkins. Philadelphia
- Gilman dan Goodman. 2011. *Dasar Farmakologi dan Terapi*. EGC. Jakarta
- Greene R.J dan Norman, D. 2008. *Pathology and Therapeutics for Pharmacist 3rd Edition*. Pharmaceutical Press. London
- Guyton AC, Hall JE. 1997. *Buku ajar fisiologi kedokteran Edisi 9*. EGC. Jakarta
- Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al., American college of rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care & Research*. 2012; 64 (4):465-474.
- Hoan T.T dan Raharja Kirana. 2013. *Obat-Obat Penting Edisi 6*. Elex Media Komputindo. Jakarta
- Ikatan Rheumatoid Indonesia. 2014. *Diagnosis dan Penatalaksanaan Osteoarthritis*. Jakarta

- Ireneu, et al. (2017). Hubungan Indeks Massa Tubuh terhadap Kejadian Osteoarthritis Lutut di RSUD Al - Ihsan Bandung (Studi di Poliklinik Reumatologi dan Saraf Periode Maret - Mei 2017). *Prosiding Pendidikan Dokter*, 3 (2): 656 - 664.
- Katzung BG. *Basic & Clinical Pharmacology 9th edition*. San Francisco, USA: The McGraw-Hill Companies; 2004; p.576-603.
- Katzung, Betram G; Susan, B.M; Anthony, J.T. 2012. *Farmakologi Dasar dan Klinik Edisi 12*. EGC. Jakarta
- Kee, Joyce L dan Evelyn R.H. 1993. *Farmakologi pendekatan proses keperawatan*. EGC. Jakarta
- Kidd B. *Mechanisms of pain in osteoarthritis*. *HSS J*. 2012 Feb;8(1):26–8.
- Koh Y, Yap CW, Li SC. *A quantitative approach of using genetic algorithm in designing a probability scoring system of an adverse drug reaction assessment system*. *Int J Med Inform*. 2008 Jun;77(6):421–30.
- Kuntono, Heru P, 2005; *Penatalaksanaan Fisioterapi pada Kondisi Osteoarthritis*; Temu Ilmiah IFI, Kediri.
- Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, et al. *A current review of molecular mechanisms regarding osteoarthritis and pain*. *Gene*. Elsevier B.V.; 2013 Sep 25;527(2):440–7.
- Loza, Estibaliz., 2008. Systematic Review: Is the Use of NSAIDs Effective and Safe in the Elderly? *Reumatology Clinical*. Vol. 4, No. 5, p.172-182
- Maharani, Eka. 2007. *Faktor-faktor Risiko Osteoarthritis Lutu (Studi Kasus Di Rumah Sakit Dokter Karadi Semarang)*. Tesis Universitas Diponegoro
- Mansjoer, A, 2001, *Kapita Selekta Kedokteran*, Jakarta : Media Aesculapius
- Nadhira Siti, 2018. “Evaluasi Penggunaan Obat NSAID (*Non Steroid Anti Inflammatory Drug*) Pada Pasien *Osteoarthritis* Rawat Jalan Di RS TNI AD ROBERT WOLTER MONGISIDI Manado”.
- Nieto, Jorge D., 2014. *Meloxicam And Glucosamine Formulation And Uses Thereof*.
- Noor, Helmi Z. 2012. *Buku Ajar Gangguan Muskuloskeletal*. Salemba Medika. Jakarta
- Notoatmodjo Soekidjo. 2010. *Metodologi Penelitian Kesehatan*. Rineka Cipta. Jakarta
- Oka Ni Made, 2016. “Perbandingan *Outcome* Nyeri Pada Pasien *Osteoarthritis* Yang Diterapi Dengan Kombinasi Diacerein dan Meloksikam atau Meloksikam Tunggal Di Poli Ortopedi RSUD dr. Mohammad Soewandhie Surabaya”.

- Pain OF, Oa IN, Implications C. *The sources of pain in osteoarthritis: a pathophysiological review*. Radiol Bras. 2014;66(1):57–71
- Philip, Conaghan. 2012. *Fast Facts: Osteoarthritis*. Health Press Limited.
- Pierre P.J et., al. 1999. *Pharmacologic Therapy of Osteoarthritis. Osteoarthritis Research Unit*. University of Montreal. Canada
- Posey L.M, et al. 2009. *Pharmacotherapy in Primary Care*. The McGraw-hill. United State of America
- Rachmawati Ema, et al. 2013. “Studi Penggunaan Obat Pada Pasien *Osteoarthritis* Usia Lanjut Di Instalasi Rawat Jalan RS dr. H. Koesnadi Bondowoso”.
- Remst DFG, Blaney Davidson EN, Vitters EL, Blom a B, Stoop R, Snabel JM, et al. *Osteoarthritis-related fibrosis is associated with both elevated pyridinoline cross-link formation and lysyl hydroxylase 2b expression*. Osteoarthritis Cartilage. Elsevier Ltd; 2013 Jan;21(1):157–64.
- Remst DFG, Blom a B, Vitters EL, Bank R a, van den Berg WB, Blaney Davidson EN, et al. *Gene expression analysis of murine and human osteoarthritis synovium reveals elevation of transforming growth factor β -responsive genes in osteoarthritis-related fibrosis*. Arthritis Rheumatol. 2014 Mar;66(3):647–56.
- Seminowicz DA, Wideman TH, Naso L, Hatami-Khoroushahi Z, Fallatah S, Ware MA, et al. *Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function*. J Neurosci. 2011 May 18; 31(20): 7540-50.
- Singhealth. 2017. *Osteoarthritis*. <https://www.singhealth.com.sg> di akses pada Jumat 31 Oktober 2017
- Snizek J.P et al. 2002. *Encyclopedia of Public Health*. Macmillan Reference. United State of America
- Soeroso, dkk. 2014. *Buku Ajar Ilmu Penyakit Dalam Edisi 6*. Internal Publishing; Jakarta
- Stacy, M.D. 2007. *Osteoarthritis in Geriatric Patients Resulting from Primary Osteoarthritis*. Journal of Bone and Boint Surgery, Vol I
- Swartz, Mark H. 2005. *Buku Ajar Diagnostik Fisik*. Jakarta. EGC
- WHO. *Requirement for Adverse Reaction Reporting*. Geneva: WHO; 1975.
- World Health Organization (WHO). *The Rational Use Of Drugs. WHO Health Assembly Resolution WHA39.27*. Geneva : World Health Organization ; 1985.
- WHO. 2017. <http://www.who.int/hospitals/en/> di akses Senin 29 Mei 2017

Wilmana, Freddy dan Sulistia Gan. 2011. Farmakologi dan Terapi. Balai Penerbit FKUI. Jakarta

